Core Insights - Phio Pharmaceuticals Corp. is presenting data on its proprietary INTASYL® siRNA gene silencing technology at the 20th Annual Oligonucleotide Therapeutics Society Meeting in Montreal from October 6th-9th, 2024 [3][4] - The presentation will highlight how INTASYL enhances the ex vivo expansion process to improve the functionality and outcomes of adoptive cell therapies, including NK, TIL, and CAR-T [4] - INTASYL technology is noted for its simplified chemical composition, which aims to reduce toxicity while improving tolerability and efficacy in therapeutic development [4][5] Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company focused on silencing specific genes using its proprietary INTASYL siRNA technology [5] - INTASYL can target and silence virtually any gene with high specificity across a wide range of tissue types, primarily enhancing the ability of immune cells to kill tumor cells [5] - INTASYL is unique as it is the only self-delivering RNAi technology that does not require specialized formulations or drug delivery systems [5]

. . Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series Presentation and live Q&A to take place Thursday, September 5, 2024, at 12 PM EDT August 29, 2024 8:30 AM EDT | Source: Phio Pharmaceuticals Corp. Marlborough, Massachusetts--(Newsfile Corp. - August 29, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effectiv ...

Core Insights - Phio Pharmaceuticals reported its financial results for Q2 2024, highlighting progress in its clinical trials and financial position [3][10]. Recent Corporate Updates - The Phase 1b clinical trial for PH-762 received a positive safety recommendation, with no dose-limiting toxicities observed, leading to dose escalation and enrollment of the next cohort [3][4]. - A fifth clinical trial site has been added at the University of Pittsburgh Medical Center, joining four other sites [5]. - A new patent for INTASYL RXI-185, targeting aging skin disorders, was granted in South Korea [6]. - The company entered into agreements to exercise warrants for 545,286 shares at a reduced price, generating approximately $3.1 million in gross proceeds [7][11]. - A reverse stock split was executed, reducing outstanding shares from approximately 4.6 million to 0.5 million [8]. - The company is now in compliance with Nasdaq's minimum bid price requirement [9]. - Robert M. Infarinato was appointed as the new CFO effective August 1, 2024 [9]. - An exploratory collaboration was initiated with a global skincare company for cosmeceutical applications [10]. Financial Results - Cash position decreased to $4.7 million as of June 30, 2024, down from $8.5 million at the end of 2023 [10]. - Research and development expenses were $0.9 million for Q2 2024, a 37% decrease from $1.4 million in Q2 2023 [12]. - General and administrative expenses decreased by 10% to $1.0 million in Q2 2024 compared to $1.2 million in Q2 2023 [13]. - The net loss for Q2 2024 was $1.8 million, down from $2.5 million in Q2 2023, primarily due to reduced expenses [14]. Operational Metrics - Total operating expenses for Q2 2024 were $1.9 million, compared to $2.5 million in Q2 2023 [19]. - The net loss per common share for Q2 2024 was $3.62, compared to $13.27 in Q2 2023 [19]. - The weighted average number of common shares outstanding was 510,188 for Q2 2024 [19]. Balance Sheet Highlights - Total assets as of June 30, 2024, were $5.3 million, down from $9.4 million at the end of 2023 [20][21]. - Cash and cash equivalents decreased to $4.7 million from $8.5 million [20]. - Total liabilities were $1.5 million, with total stockholders' equity at $3.8 million [21].

Marlborough, Massachusetts--(Newsfile Corp. - August 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced the appointment of Robert M. Infarinato to the position of vice president and chief financial officer effective August 1, 2024. He will serve in the capacity of Principal Financial Officer including responsibility for a ...

. July 12, 2024 8:00 AM EDT | Source: Phio Pharmaceuticals Corp. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash and the payment of additional $0.125 per new unregistered warrant (additional $136,321.50 in the aggregate, which are included in the gross proceeds to the Company), the exercising holders will receive new unregistered warrants to purchase shares of common stock in a private placement pursuant ...

. . . Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762 July 08, 2024 8:00 AM EDT | Source: Phio Pharmaceuticals Corp. Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts--(Newsfile Corp. - July 8, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, t ...

Marlborough, Massachusetts--(Newsfile Corp. - July 2, 2024) - Phio Pharmaceuticals Corp. (Nasdaq: PHIO) (the "Company"), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1- for-9. The reverse stock split will become effective at 12:01 a.m. Eastern Time on Ju ...

Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) Phio to present a clinical study progress update on their lead clinical candidate, PH-762 May 23, 2024 5:00 PM EDT | Source: Phio Pharmaceuticals Corp. Marlborough, Massachusetts--(Newsfile Corp. - May 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more e ...

Registration No. 333- As filed with the Securities and Exchange Commission on May 17, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Phio Pharmaceuticals Corp. (Exact name of registrant as specified in its charter) Delaware 45-3215903 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 11 Apex Drive, Suite 300A, PMB 2006 Marlborough, Massachusetts 01752 (508) 767-386 ...

MARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it has entered into a purchase agreement with TRITON Funds. Subject to the terms of the purchase agreement, TRITON will purchase up to approximately 18.8% of Phio's common shares yielding gross proceeds of up to $621,000 to the Co ...